These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 33341308)
21. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories. Rudenko L; Yeolekar L; Kiseleva I; Isakova-Sivak I Vaccine; 2016 Oct; 34(45):5436-5441. PubMed ID: 27593158 [TBL] [Abstract][Full Text] [Related]
22. Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers. Wahid R; Holt R; Hjorth R; Berlanda Scorza F Vaccine; 2016 Oct; 34(45):5430-5435. PubMed ID: 27484011 [TBL] [Abstract][Full Text] [Related]
23. Lessons learned from the COVID-19 pandemic for improved influenza control. Palache A; Billingsley JK; MacLaren K; Morgan L; Rockman S; Barbosa P; Vaccine; 2023 Sep; 41(40):5877-5883. PubMed ID: 37598027 [TBL] [Abstract][Full Text] [Related]
24. A pandemic influenza vaccine in India: from strain to sale within 12 months. Dhere R; Yeolekar L; Kulkarni P; Menon R; Vaidya V; Ganguly M; Tyagi P; Barde P; Jadhav S Vaccine; 2011 Jul; 29 Suppl 1():A16-21. PubMed ID: 21684421 [TBL] [Abstract][Full Text] [Related]
25. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges. Hessel L; Influenza Other Respir Viruses; 2009 Jul; 3(4):165-70. PubMed ID: 19627373 [TBL] [Abstract][Full Text] [Related]
26. Development of pandemic influenza vaccine production capacity in Viet Nam. Hoa LK; Hiep LV; Be LV Vaccine; 2011 Jul; 29 Suppl 1():A34-6. PubMed ID: 21684426 [TBL] [Abstract][Full Text] [Related]
27. Shaping meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness. Ruscio B; Bolster A; Bresee J; Vaccine; 2020 Apr; 38(16):3179-3183. PubMed ID: 32171576 [TBL] [Abstract][Full Text] [Related]
28. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T; Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877 [TBL] [Abstract][Full Text] [Related]
29. Improving pandemic preparedness through better, faster influenza vaccines. Newland M; Durham D; Asher J; Treanor JJ; Seals J; Donis RO; Johnson RA Expert Rev Vaccines; 2021 Mar; 20(3):235-242. PubMed ID: 33576708 [No Abstract] [Full Text] [Related]
30. Prioritization strategies for pandemic influenza vaccine in 27 countries of the European Union and the Global Health Security Action Group: a review. Straetemans M; Buchholz U; Reiter S; Haas W; Krause G BMC Public Health; 2007 Sep; 7():236. PubMed ID: 17825095 [TBL] [Abstract][Full Text] [Related]
31. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. ; Ampofo WK; Baylor N; Cobey S; Cox NJ; Daves S; Edwards S; Ferguson N; Grohmann G; Hay A; Katz J; Kullabutr K; Lambert L; Levandowski R; Mishra AC; Monto A; Siqueira M; Tashiro M; Waddell AL; Wairagkar N; Wood J; Zambon M; Zhang W Influenza Other Respir Viruses; 2012 Mar; 6(2):142-52, e1-5. PubMed ID: 21819547 [TBL] [Abstract][Full Text] [Related]
33. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Sparrow E; Friede M; Sheikh M; Torvaldsen S; Newall AT Vaccine; 2016 Oct; 34(45):5442-5448. PubMed ID: 27622299 [TBL] [Abstract][Full Text] [Related]
34. Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic. Porter RM; Goldin S; Lafond KE; Hedman L; Ungkuldee M; Kurzum J; Azziz-Baumgartner E; Nannei C; Bresee JS; Moen A Vaccine; 2020 Jan; 38(5):1152-1159. PubMed ID: 31839465 [TBL] [Abstract][Full Text] [Related]
35. Considerations for sustainable influenza vaccine production in developing countries. Nannei C; Chadwick C; Fatima H; Goldin S; Grubo M; Ganim A Vaccine; 2016 Oct; 34(45):5425-5429. PubMed ID: 27614783 [TBL] [Abstract][Full Text] [Related]
36. Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Vemula SV; Mittal SK Expert Opin Biol Ther; 2010 Oct; 10(10):1469-87. PubMed ID: 20822477 [TBL] [Abstract][Full Text] [Related]
37. Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity. Innis BL; Berlanda Scorza F; Blum JS; Jain VK; Older Aguilar A; Post DJ; Roberts PC; Wairagkar N; White J; Bresee J Vaccine; 2019 Aug; 37(35):4823-4829. PubMed ID: 31362819 [TBL] [Abstract][Full Text] [Related]
38. Pandemic influenza and the global vaccine supply. Fedson DS Clin Infect Dis; 2003 Jun; 36(12):1552-61. PubMed ID: 12802755 [TBL] [Abstract][Full Text] [Related]
39. Seasonal influenza vaccine dose distribution in 195 countries (2004-2013): Little progress in estimated global vaccination coverage. Palache A; Oriol-Mathieu V; Fino M; Xydia-Charmanta M; Vaccine; 2015 Oct; 33(42):5598-5605. PubMed ID: 26368399 [TBL] [Abstract][Full Text] [Related]
40. An international technology platform for influenza vaccines. Hendriks J; Holleman M; de Boer O; de Jong P; Luytjes W Vaccine; 2011 Jul; 29 Suppl 1():A8-11. PubMed ID: 21684431 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]